Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Smith

Orthopaedic Surgery of the Spine Orange, CA Medical Doctor

NPI 1629257688 CMS profile 255729

280 S Main St, Suite 200, Orange, CA 92868

Open in the dashboard

General payments

$856,320

729 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$65,325 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeremy Smith of Orange, CA is reported in the CMS Open Payments database as having received $856,320 across 729 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $65,325 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122,933 116
2024 General $98,930 94
2023 General $187,859 85
2022 General $217,826 152
2021 General $81,799 106
2020 General $86,083 92
2019 General $60,890 84

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Smith
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Jeremy Smith were reported at $122,933. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Jeremy Smith Orthopaedic Surgery of the Spine median Middle half National median
2019 $60,890 $2,106 $337–$18,608 $163
2020 $86,083 $1,213 $156–$15,082 $114
2021 $81,799 $1,834 $271–$15,617 $132
2022 $217,826 $2,015 $320–$17,036 $149
2023 $187,859 $1,925 $336–$14,599 $160
2024 $98,930 $2,110 $341–$12,483 $164
2025 $122,933 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NuVasive, Inc. $380,896 287 payments
  2. Globus Medical, Inc. $183,507 134 payments
  3. Spineart USA Inc $144,438 165 payments
  4. Spineart SA $90,884 11 payments
  5. RTI Surgical, Inc. $23,940 32 payments
  6. Xtant Medical Inc $14,714 7 payments
  7. Innovasis Inc $13,549 9 payments
  8. Baxter Healthcare $954 17 payments
  9. Orthofix Medical, Inc. $707 3 payments
  10. Medtronic, Inc. $565 8 payments
  11. Other $2,165 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $593,768 47 payments
  2. Travel and Lodging $122,028 87 payments
  3. Consulting Fee $102,750 51 payments
  4. Food and Beverage $37,755 541 payments
  5. Gift $10 2 payments
  6. Education $10 1 payment
Products named General payments · program years 2019–2025
  1. COHERE Spine/Spine Surgery $393,222 33 payments
  2. Pulse $64,441 39 payments
  3. PERLA TL $46,576 61 payments
  4. Scarlet AC Orthopedic Surgery $43,256 2 payments
  5. COHERE Spine/Spine Surgery $39,481 12 payments
  6. Scarlet AC Orthopedics $30,935 2 payments
  7. CoRoent $27,049 3 payments
  8. PERLA C $26,290 10 payments
  9. BAGUERA C $25,133 7 payments
  10. CORTERA $17,698 13 payments
  11. Other $101,730 493 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,897

Median for Orthopedic Surgery: 203

Drug cost

$47,465

Median for Orthopedic Surgery: $1,433

Branded share of claims

6.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Teriparatide Generic 12 $29,411
Gabapentin Generic 300 $2,990
Lidocaine Generic 21 $2,530
Pregabalin Generic 90 $1,759
Oxycodone Hcl Generic 141 $1,644
Celecoxib Generic 68 $1,505
Baclofen Generic 124 $1,451
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 94 $1,228
Methocarbamol Generic 86 $1,057
Prednisone Generic 310 $732

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 124 billing codes

Paid by Medicare

$860,677

Of which drugs: $4,504

Medicare patients

1,011

Average age 75

Services billed

6,755

578 women, 433 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 29%
Osteoporosis 28%
Diabetes 24%
Depression 24%
Chronic kidney disease 21%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 119 421 $2,223
Injection, ketorolac tromethamine, per 15 mg J1885 Office 20 79 $33
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 42 $32

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TERIPARATIDE
  • Alvogen Inc $18
$18 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

729 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record